Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity.

ABSTRACT: Clinical trials in cancer are ideally built on a foundation of sound mechanistic rationale and well-validated drug activity in relevant disease models. The screening of approved and investigational drugs in cell-based phenotypic assays can provide evidence of drug activity, but alternative screening paradigms are needed to develop and optimize multidrug combination regimens. Here, we utilize in vitro screening outcomes across a panel of lymphoma cell lines to dissect the activity of four small-molecule drugs (Venetoclax, Ibrutinib, Prednisolone, and Lenalidomide) currently under investigation within ongoing clinical trials in lymphoma. Data from multiple concentration ranges and time points show that synergistic drug combinations promote apoptosis and cytotoxicity responses at concentratio

SUBMITTER: Ceribelli M 

PROVIDER: S-EPMC11626182 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature